This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
subcutaneous injection
New Haven Pfizer Clinical Research Unit (NH PCRU)
New Haven, Connecticut, United States
RECRUITINGTilrekimig area under the serum concentration-time curve from time zero to infinity (AUCinf)
Time frame: pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post -dose
Tilrekimig Maximum Observed Plasma Concentration (Cmax)
Time frame: pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post dose
Incidence of Treatment-emergent adverse events
Time frame: Baseline through day 150
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.